1 August 2020 in European Urology
1 November 2015 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Background: Other than Kaposi sarcoma (KS)–associated herpesvirus and CD4+ T-cell lymphopenia, the mechanisms responsible for KS in the context of HIV are poorly understood. One recently explored pathway of HIV pathogenesis involves induction of the enzyme indoleamine 2,3-dioxygenase-1 (IDO), which catabolizes tryptophan into kynurenine and several other immunologically active metabolites that suppress T-cell proliferation. We investigated the role of IDO in the development of KS in HIV disease. Methods: In a case–control study among untreated HIV-infected Ugandans, cases were adults with KS and controls were without KS. IDO activity was assessed by the ratio of plasma kynurenine to tryptophan levels (KT ratio), measured by liquid chromatography–tandem mass spectrometry. Results: We studied 631 HIV-infected subjects: 222 KS cases and 409 controls. Non-KS controls had a higher median plasma KT ratio (130, interquartile range: 90 to 190 nM/μM) than KS cases (110, interquartile range: 90 to 150 nM/μM) (P = 0.004). After adjustment for age, sex, CD4 count, and plasma HIV RNA level, subjects with the highest (fourth quartile) plasma KT ratios had a 59% reduction (95% confidence interval: 27% to 77%) in the odds of KS compared with those with the lowest (first quartile) levels. KS was also independently associated with lower CD4+ count, higher plasma HIV RNA, and men. Conclusions: Among HIV-infected individuals, greater activity of the kynurenine pathway of tryptophan catabolism, as evidenced by higher levels of plasma KT ratio, was associated with lower occurrence of KS. Some consequences of immune activation in HIV infection might actually suppress certain cancers.
5 June 2020 in Frontiers in Medicine
Background: It was a difficult question to identify candidates who would benefit most from adjuvant chemotherapy in stage II colon cancer because of the paucity of relevant conclusive clinical trial results. We aimed to assess if mucinous adenocarcinoma (MUA) could be an indicator for the efficacy of adjuvant chemotherapy in stage II colon cancer. Methods:Using SEER*Stat software V.8.3.5, eligible patients were then recruited from the SEER database. A χ2 test was applied to compare the distribution of different categorical variables between nonmucinous adenocarcinoma (NMUA) and MUA groups. We then used the Kaplan–Meier method to analyze overall survival (OS) of different histological types in stage II colon cancer, and the log-rank test was then used to assess the OS differences. The Cox proportional regression risk models were also built in our analyses to eliminate potential crossed bias from other prognostic factors. Results:A total of 50,065 patients diagnosed with stage II colon cancer were recruited from the SEER database from 2004 to 2011; all the patients were divided into two groups, including NMUA (n = 44,785) and MUA (n = 5,280). The Cox analysis of the histological type indicated that the survival difference between MUA and NMUA failed to reach statistical significance in stage II colon cancer (P = 0.360). In NMUA, patients treated with adjuvant chemotherapy were independently associated with 37.2% decreased risk of overall mortality compared with those not [hazard ratio (HR) = 0.628, 95% confidence interval (CI) = 0.601-1.656, P < 0.001]; in MUA, the number increased to 41.5% (HR = 0.585, 95% CI = 0.515-0.665, P < 0.001). Conclusions:Our study showed that the survival difference between MUA and NMUA failed to reach statistical significance in stage II colon cancer. More importantly, our study had provided the first evidence that chemotherapy would offer higher survival improvement in MUA compared with NMUA in stage II colon cancer; mucinous histology might be an indicator for enhanced survival benefit of chemotherapy in stage II colon cancer.
20 May 2016 in Journal of Clinical Oncology
e12566 Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited effective treatment options. New therapeutic approaches are urgently needed to improve the prognosis of TNBC. We studied the character of Runx2 gene in breast cancer and whether the Runx2-dendritic cell (DC) vaccine can induce specific antitumor effect on triple negative breast cancer in vitro. Methods: The expression of Runx2 in triple negative breast cancer,non-triple negative breast cancer and normal breast cells were analyzed by RT-PCR,immunocytochemistry and westernblot. DC were isolated and cultured from peripheral blood of healthy donors, the surface maker CD11c, CD80, CD86 and HLA-DR were analyzed with flow cytometry. Runx2 lentivirus were prepared to infect DC and divided in transfected group, negative group and blank group. Fluorescence microscope, PCR and Westernblot tested its transfection efficiency of all groups. DC and T cells were cultured together to induce CTL, ELISA was used to detect the secretion of IL-12 and IFN-γ. The killing ability of CTL were calculated by MTT. Results: PCR results shown the ΔCT value of Runx2 in MDA –MB -231,MCF7 and MCF10A were 10.37±0.61, 11.86±0.59, 12.97±0.06(P < 0.05)respectively. Both immunocytochemistry and westernblot showed Runx2 were strongly positive in MDA –MB -231, but weaker in MCF7 and MCF10A.In this study, Runx2-lentivirus were prepared and transfected DC. Rich green flurescent confirmed that the Runx2 gene were successfully turned into mature DC .Then the transfected DC were co-cultured with T cells, and the secretion of IL-12、IFN-γ(pg/ml)were measured as 170.33±5.03、517.15±5.88. While the secretion of IL-12、IFN-γ were 72.30±3.05、171.57±1.37(P < 0.05)in non-transfected group. And the killing ratio of cytotoxic T cells of transfected group on triple negative breast cancer was 60.02±3.51 compared with 25.57±3.64(P < 0.05)of the control group. Conclusions: Runx2 maybe a new target for triple negative breast cancer treatment. Runx2 can transduce DC successfully and the vaccine induce specific CTL and strong cytotoxicity against triple negative breast cancer.